➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
Colorcon
Mallinckrodt
McKinsey

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202813


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 202813 describes QNASL, which is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the QNASL profile page.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.
Summary for 202813
Tradename:QNASL
Applicant:Teva Branded Pharm
Ingredient:beclomethasone dipropionate
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 202813
Suppliers and Packaging for NDA: 202813
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813 NDA Teva Respiratory, LLC 59310-406 59310-406-06 1 INHALER in 1 CARTON (59310-406-06) > 60 AEROSOL, METERED in 1 INHALER
QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813 NDA Teva Respiratory, LLC 59310-406 59310-406-08 1 INHALER in 1 CARTON (59310-406-08) > 60 AEROSOL, METERED in 1 INHALER

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;NASALStrength0.08MG/ACTUATION
Approval Date:Mar 23, 2012TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Oct 21, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Jan 24, 2027Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;NASALStrength0.04MG/ACTUATION
Approval Date:Dec 17, 2014TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Oct 21, 2031Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 202813

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014   Start Trial   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012   Start Trial   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Boehringer Ingelheim
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.